• Je něco špatně v tomto záznamu ?

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis

LT. van Hulsteijn, R. Pasquali, F. Casanueva, M. Haluzik, S. Ledoux, MP. Monteiro, J. Salvador, F. Santini, H. Toplak, OM. Dekkers,

. 2020 ; 182 (1) : 11-21. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005757

Objective: The increasing prevalence of obesity is expected to promote the demand for endocrine testing. To facilitate evidence guided testing, we aimed to assess the prevalence of endocrine disorders in patients with obesity. The review was carried out as part of the Endocrine Work-up for the Obesity Guideline of the European Society of Endocrinology. Design: Systematic review and meta-analysis of the literature. Methods: A search was performed in MEDLINE, EMBASE, Web of Science and COCHRANE Library for original articles assessing the prevalence of hypothyroidism, hypercortisolism, hypogonadism (males) or hyperandrogenism (females) in patients with obesity. Data were pooled in a random-effects logistic regression model and reported with 95% confidence intervals (95% CI). Results: Sixty-eight studies were included, concerning a total of 19.996 patients with obesity. The pooled prevalence of overt (newly diagnosed or already treated) and subclinical hypothyroidism was 14.0% (95% CI: 9.7-18.9) and 14.6% (95% CI: 9.2-20.9), respectively. Pooled prevalence of hypercortisolism was 0.9% (95% CI: 0.3-1.6). Pooled prevalence of hypogonadism when measuring total testosterone or free testosterone was 42.8% (95% CI: 37.6-48.0) and 32.7% (95% CI: 23.1-43.0), respectively. Heterogeneity was high for all analyses. Conclusions: The prevalence of endocrine disorders in patients with obesity is considerable, although the underlying mechanisms are complex. Given the cross-sectional design of the studies included, no formal distinction between endocrine causes and consequences of obesity could be made.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005757
003      
CZ-PrNML
005      
20200525102827.0
007      
ta
008      
200511s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/EJE-19-0666 $2 doi
035    __
$a (PubMed)31652416
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a van Hulsteijn, L T $u Department of Clinical Endocrinology and Metabolism, University Medical Centre Groningen, Groningen, The Netherlands.
245    10
$a Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis / $c LT. van Hulsteijn, R. Pasquali, F. Casanueva, M. Haluzik, S. Ledoux, MP. Monteiro, J. Salvador, F. Santini, H. Toplak, OM. Dekkers,
520    9_
$a Objective: The increasing prevalence of obesity is expected to promote the demand for endocrine testing. To facilitate evidence guided testing, we aimed to assess the prevalence of endocrine disorders in patients with obesity. The review was carried out as part of the Endocrine Work-up for the Obesity Guideline of the European Society of Endocrinology. Design: Systematic review and meta-analysis of the literature. Methods: A search was performed in MEDLINE, EMBASE, Web of Science and COCHRANE Library for original articles assessing the prevalence of hypothyroidism, hypercortisolism, hypogonadism (males) or hyperandrogenism (females) in patients with obesity. Data were pooled in a random-effects logistic regression model and reported with 95% confidence intervals (95% CI). Results: Sixty-eight studies were included, concerning a total of 19.996 patients with obesity. The pooled prevalence of overt (newly diagnosed or already treated) and subclinical hypothyroidism was 14.0% (95% CI: 9.7-18.9) and 14.6% (95% CI: 9.2-20.9), respectively. Pooled prevalence of hypercortisolism was 0.9% (95% CI: 0.3-1.6). Pooled prevalence of hypogonadism when measuring total testosterone or free testosterone was 42.8% (95% CI: 37.6-48.0) and 32.7% (95% CI: 23.1-43.0), respectively. Heterogeneity was high for all analyses. Conclusions: The prevalence of endocrine disorders in patients with obesity is considerable, although the underlying mechanisms are complex. Given the cross-sectional design of the studies included, no formal distinction between endocrine causes and consequences of obesity could be made.
650    _2
$a průřezové studie $7 D003430
650    _2
$a nemoci endokrinního systému $x epidemiologie $x etiologie $7 D004700
650    _2
$a hypotyreóza $x epidemiologie $x etiologie $7 D007037
650    _2
$a obezita $x komplikace $x epidemiologie $7 D009765
650    _2
$a prevalence $7 D015995
650    _2
$a hodnocení rizik $7 D018570
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
700    1_
$a Pasquali, R $u University Alma Mater Studiorum, Bologna, Italy.
700    1_
$a Casanueva, F $u Department of Medicine, Santiago de Compostela University, Complejo Hospitalario Universitario de Santiago (CHUS), CIBER de Fisiopatologia Obesidad y Nutricion (CIBERobn), Instituto Salud Carlos III, Santiago de Compostela, Spain.
700    1_
$a Haluzik, M $u Diabetes Centre and Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine and Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Ledoux, S $u Department of Physiology, Obesity Center, Louis Mourier Hospital (APHP), Colombes and Paris Diderot University, Paris, France.
700    1_
$a Monteiro, M P $u Endocrine, Cardiovascular & Metabolic Research, Unit for Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Oporto, Porto, Portugal. Honorary Clinical Senior Lecturer and Obesity Consultant, University College of London, London, UK.
700    1_
$a Salvador, J $u Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain. CIBEROBN, Instituto Carlos III, Madrid, Spain.
700    1_
$a Santini, F $u Obesity and Lipodystrophy Center, University Hospital of Pisa, Pisa, Italy.
700    1_
$a Toplak, H $u Division of Endocrinology and Diabetology, Department of Medicine, Medical University of Graz, Graz, Austria.
700    1_
$a Dekkers, O M $u Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands. Department of Clinical Endocrinology and Metabolism, Leiden University Medical Centre, Leiden, The Netherlands. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
773    0_
$w MED00009634 $t European journal of endocrinology $x 1479-683X $g Roč. 182, č. 1 (2020), s. 11-21
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31652416 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200525102827 $b ABA008
999    __
$a ok $b bmc $g 1524615 $s 1095813
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 182 $c 1 $d 11-21 $e - $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace